Table 3 Changes in brain volumes from baseline in ALZ2002 to the end of the double-blind period in ALZ2004, by treatment group (safety analysis set)
Dosage | Region | Preclinical AD | MCI due to AD | ||||||
|---|---|---|---|---|---|---|---|---|---|
Double blind week 24 | Double blind week 52 | Double blind week 24 | Double blind week 52 | ||||||
n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | ||
Placebo | Total hippocampus | 6 | − 61.183 (152.8617) | 4 | − 192.691 (286.0535) | 23 | − 148.955 (110.0055) | 16 | − 208.173 (139.2326) |
Bilateral ventricles | 6 | 1213.479 (1297.2666) | 4 | 2384.305 (1765.8039) | 23 | 1877.688 (1868.2961) | 16 | 2554.255 (1619.2302) | |
Whole brain | 6 | − 4513.446 (6744.6900) | 4 | − 3966.134 (6897.1749) | 21 | − 5202.949 (5310.6112) | 15 | − 6398.921 (6057.7712) | |
10 mg | Total hippocampus | 8 | − 130.472 (133.3899) | 4 | − 314.289 (190.6022) | 18 | −130.601 (100.9252) | 16 | − 308.766 (198.3581) |
Bilateral ventricles | 8 | 1317.472 (1089.6703) | 4 | 3254.365 (1326.9982) | 18 | 1294.812 (1190.6962) | 16 | 3349.908 (2563.2821) | |
Whole brain | 8 | − 7197.703 (7409.7046) | 4 | − 17,698.910 (5463.6862) | 17 | − 5736.212 (6275.3521) | 16 | − 10,815.252 (9814.0704) | |
25 mg | Total hippocampus | 5 | −12.221 (92.4995) | 5 | − 129.273 (81.0670) | 16 | − 122.374 (86.0882) | 13 | − 235.946 (145.2177) |
Bilateral ventricles | 5 | 538.445 (965.7828) | 5 | 1999.089 (1514.6993) | 16 | 1399.116 (1085.9684) | 13 | 2853.589 (1945.9111) | |
Whole brain | 5 | − 1144.502 (7511.2280) | 5 | − 4524.925 (6112.8815) | 14 | − 6634.464 (5868.5297) | 13 | − 9624.766 (8707.2218) | |